Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials
Charles M. Perou(University of North Carolina at Chapel Hill), Thérese Sørlie(Norwegian Cancer Society), Simen Myhre(Oslo University Hospital), Trine Tramm(Aarhus University Hospital), Tinne Laurberg(Aarhus University Hospital), Silje Nord(Oslo University Hospital), Torsten O. Nielsen(University of British Columbia), Karen A. Gelmon(University of British Columbia), Jens Overgaard(Aarhus University), Jan Alsner(Aarhus University Hospital), Aleix Prat(Hospital Clínic de Barcelona), Cheng Fan(University of North Carolina at Chapel Hill), Maggie C.U. Cheang(Institute of Cancer Research), David Voduc(BC Cancer Agency), Samuel Leung(BC Cancer Agency)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k